tetano
Editor, Senior Moderator
Clin Infect Dis
. 2020 Jun 4;ciaa709.
doi: 10.1093/cid/ciaa709. Online ahead of print.
Alterations of the Gut Microbiota in Patients With COVID-19 or H1N1 Influenza
Silan Gu[SUP] 1 [/SUP], Yanfei Chen[SUP] 1 [/SUP], Zhengjie Wu[SUP] 1 [/SUP], Yunbo Chen[SUP] 1 [/SUP], Hainv Gao[SUP] 2 [/SUP], Longxian Lv[SUP] 1 [/SUP], Feifei Guo[SUP] 2 [/SUP], Xuewu Zhang[SUP] 3 [/SUP], Rui Luo[SUP] 1 [/SUP], Chenjie Huang[SUP] 1 [/SUP], Haifeng Lu[SUP] 1 [/SUP], Beiwen Zheng[SUP] 1 [/SUP], Jiaying Zhang[SUP] 1 [/SUP], Ren Yan[SUP] 1 [/SUP], Hua Zhang[SUP] 1 [/SUP], Huiyong Jiang[SUP] 1 [/SUP], Qiaomai Xu[SUP] 1 [/SUP], Jing Guo[SUP] 1 [/SUP], Yiwen Gong[SUP] 1 [/SUP], Lingling Tang[SUP] 2 [/SUP], Lanjuan Li[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is an emerging serious global health problem. Gastrointestinal symptoms are common in COVID-19 patients, and SARS-CoV-2 RNA has been detected in stool specimens. However, the relationship between the gut microbiome and disease remains to be established.
Methods: We conducted a cross-sectional study of 30 COVID-19 patients, 24 influenza A (H1N1) patients, and 30 matched healthy controls (HC) to identify differences in the gut microbiota by 16S ribosomal RNA (rRNA) gene V3-V4 region sequencing.
Results: Compared with HC, COVID-19 patients had significantly reduced bacterial diversity, a significantly higher relative abundance of opportunistic pathogens, such as Streptococcus, Rothia, Veillonella and Actinomyces, and a lower relative abundance of beneficial symbionts. Five biomarkers showed high accuracy for distinguishing COVID-19 patients from HC with an area under the curve (AUC) up to 0.89. Patients with H1N1 displayed lower diversity and different overall microbial composition compared with COVID-19 patients. Seven biomarkers were selected to distinguish the two cohorts with an AUC of 0.94.
Conclusion: The gut microbial signature of patients with COVID-19 was different from that of H1N1 patients and HC. Our study suggests the potential value of the gut microbiota as a diagnostic biomarker and therapeutic target for COVID-19, but further validation is needed.
Keywords: COVID-19; H1N1; biomarker; dysbiosis; intestinal microbiota.
. 2020 Jun 4;ciaa709.
doi: 10.1093/cid/ciaa709. Online ahead of print.
Alterations of the Gut Microbiota in Patients With COVID-19 or H1N1 Influenza
Silan Gu[SUP] 1 [/SUP], Yanfei Chen[SUP] 1 [/SUP], Zhengjie Wu[SUP] 1 [/SUP], Yunbo Chen[SUP] 1 [/SUP], Hainv Gao[SUP] 2 [/SUP], Longxian Lv[SUP] 1 [/SUP], Feifei Guo[SUP] 2 [/SUP], Xuewu Zhang[SUP] 3 [/SUP], Rui Luo[SUP] 1 [/SUP], Chenjie Huang[SUP] 1 [/SUP], Haifeng Lu[SUP] 1 [/SUP], Beiwen Zheng[SUP] 1 [/SUP], Jiaying Zhang[SUP] 1 [/SUP], Ren Yan[SUP] 1 [/SUP], Hua Zhang[SUP] 1 [/SUP], Huiyong Jiang[SUP] 1 [/SUP], Qiaomai Xu[SUP] 1 [/SUP], Jing Guo[SUP] 1 [/SUP], Yiwen Gong[SUP] 1 [/SUP], Lingling Tang[SUP] 2 [/SUP], Lanjuan Li[SUP] 1 [/SUP]
Affiliations
- PMID: 32497191
- DOI: 10.1093/cid/ciaa709
Abstract
Background: Coronavirus disease 2019 (COVID-19) is an emerging serious global health problem. Gastrointestinal symptoms are common in COVID-19 patients, and SARS-CoV-2 RNA has been detected in stool specimens. However, the relationship between the gut microbiome and disease remains to be established.
Methods: We conducted a cross-sectional study of 30 COVID-19 patients, 24 influenza A (H1N1) patients, and 30 matched healthy controls (HC) to identify differences in the gut microbiota by 16S ribosomal RNA (rRNA) gene V3-V4 region sequencing.
Results: Compared with HC, COVID-19 patients had significantly reduced bacterial diversity, a significantly higher relative abundance of opportunistic pathogens, such as Streptococcus, Rothia, Veillonella and Actinomyces, and a lower relative abundance of beneficial symbionts. Five biomarkers showed high accuracy for distinguishing COVID-19 patients from HC with an area under the curve (AUC) up to 0.89. Patients with H1N1 displayed lower diversity and different overall microbial composition compared with COVID-19 patients. Seven biomarkers were selected to distinguish the two cohorts with an AUC of 0.94.
Conclusion: The gut microbial signature of patients with COVID-19 was different from that of H1N1 patients and HC. Our study suggests the potential value of the gut microbiota as a diagnostic biomarker and therapeutic target for COVID-19, but further validation is needed.
Keywords: COVID-19; H1N1; biomarker; dysbiosis; intestinal microbiota.